Myeloproliferative Neoplasms, Version 3.2022

Aaron T. Gerds, Jason Gotlib, Haris Ali, Prithviraj Bose, Andrew Dunbar, Amro Elshoury, Tracy I. George, Krishna Gundabolu, Elizabeth Hexner, Gabriela S. Hobbs, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Animesh PardananiNikolai Podoltsev, Lindsay Rein, Rachel Salit, Brady L. Stein, Moshe Talpaz, Pankit Vachhani, Martha Wadleigh, Sarah Wall, Dawn C. Ward, Mary Anne Bergman, Cindy Hochstetler

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.

Original languageEnglish
Pages (from-to)1033-1062
Number of pages30
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number9
DOIs
StatePublished - Sep 2022

Fingerprint

Dive into the research topics of 'Myeloproliferative Neoplasms, Version 3.2022'. Together they form a unique fingerprint.

Cite this